In the collaboration, Boehringer peptides will be developed for inhalation using Syntonix’ SynFusion drugs and Transceptor technology.
Under the terms of the agreement, Syntonix will receive an upfront fee and research support. Boehringer Ingelheim has the option to develop and commercialize the peptide candidates. Syntonix will receive milestone and royalty payments on any products developed and commercialized under the agreement.
“We believe that Syntonix’ Transceptor and SynFusion technologies have the potential to create significant improvements in the pulmonary delivery of peptides to treat serious human diseases,” commented Dr Mikael Dolsten, head of corporate division pharma research Boehringer Ingelheim.
Syntonix’ SynFusion drugs link the Fc region of an antibody to a drug in a novel manner, providing longer-acting therapeutic proteins or peptides that are injected less frequently.
The company’s Transceptor technology uses the FcRn transport pathway to enable the pulmonary delivery of SynFusion drugs with high systemic bioavailability. Transceptor allows patients to breathe normally using existing marketed inhaler devices.